SG11202012241RA - Erk inhibitor and use thereof - Google Patents
Erk inhibitor and use thereofInfo
- Publication number
- SG11202012241RA SG11202012241RA SG11202012241RA SG11202012241RA SG11202012241RA SG 11202012241R A SG11202012241R A SG 11202012241RA SG 11202012241R A SG11202012241R A SG 11202012241RA SG 11202012241R A SG11202012241R A SG 11202012241RA SG 11202012241R A SG11202012241R A SG 11202012241RA
- Authority
- SG
- Singapore
- Prior art keywords
- erk inhibitor
- erk
- inhibitor
- Prior art date
Links
- 239000012824 ERK inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018090385 | 2018-06-08 | ||
CN2018120975 | 2018-12-13 | ||
PCT/CN2019/090221 WO2019233457A1 (fr) | 2018-06-08 | 2019-06-06 | Inhibiteur d'erk et son utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202012241RA true SG11202012241RA (en) | 2021-01-28 |
Family
ID=68770778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202012241RA SG11202012241RA (en) | 2018-06-08 | 2019-06-06 | Erk inhibitor and use thereof |
Country Status (11)
Country | Link |
---|---|
US (1) | US11466013B2 (fr) |
EP (1) | EP3805217A4 (fr) |
JP (1) | JP2021525783A (fr) |
KR (1) | KR20210018915A (fr) |
CN (1) | CN112204024B (fr) |
AU (1) | AU2019280356B2 (fr) |
CA (1) | CA3103055A1 (fr) |
IL (1) | IL279276A (fr) |
SG (1) | SG11202012241RA (fr) |
TW (1) | TW202016102A (fr) |
WO (1) | WO2019233457A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3160903A1 (fr) * | 2019-12-06 | 2021-06-10 | Medshine Discovery Inc. | Compose de thiazololactame utilise en tant qu'inhibiteur d'erk et son utilisation |
TWI809904B (zh) * | 2021-06-02 | 2023-07-21 | 大陸商南京明德新藥研發有限公司 | 一種二甲基取代的噻唑並吡咯酮類化合物的晶型及其製備方法 |
WO2022268065A1 (fr) * | 2021-06-22 | 2022-12-29 | Fochon Biosciences, Ltd. | Composés en tant qu'inhibiteurs d'erk |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0104424A (pt) * | 2000-02-05 | 2002-01-08 | Vertex Pharma | Composições de pirazol úteis como inibidores de erk |
GB0614070D0 (en) * | 2006-07-14 | 2006-08-23 | Glaxo Group Ltd | Compounds |
US8211927B2 (en) * | 2007-08-02 | 2012-07-03 | MSD, Oss B.V. | 5-phenyl-isoxazole-3-carboxamide derivatives as TRPV1 modulators |
WO2016026078A1 (fr) * | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Composés hétérocycliques utilisés comme inhibiteurs de erk |
EP3842429B1 (fr) | 2015-06-15 | 2022-09-07 | Asana BioSciences, LLC | Inhibiteurs hétérocycliques de erk1 et erk2 et leur utilisation dans le traitement du cancer |
WO2017080980A1 (fr) * | 2015-11-09 | 2017-05-18 | Astrazeneca Ab | Dérivés de dihydropyrrolopyrazinone utiles dans le traitement du cancer |
-
2019
- 2019-06-06 JP JP2020568258A patent/JP2021525783A/ja active Pending
- 2019-06-06 EP EP19815477.5A patent/EP3805217A4/fr not_active Withdrawn
- 2019-06-06 TW TW108119658A patent/TW202016102A/zh unknown
- 2019-06-06 CN CN201980031574.6A patent/CN112204024B/zh active Active
- 2019-06-06 US US16/973,335 patent/US11466013B2/en active Active
- 2019-06-06 WO PCT/CN2019/090221 patent/WO2019233457A1/fr unknown
- 2019-06-06 CA CA3103055A patent/CA3103055A1/fr active Pending
- 2019-06-06 AU AU2019280356A patent/AU2019280356B2/en not_active Expired - Fee Related
- 2019-06-06 SG SG11202012241RA patent/SG11202012241RA/en unknown
- 2019-06-06 KR KR1020217000434A patent/KR20210018915A/ko not_active Application Discontinuation
-
2020
- 2020-12-08 IL IL279276A patent/IL279276A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL279276A (en) | 2021-01-31 |
US20210261552A1 (en) | 2021-08-26 |
US11466013B2 (en) | 2022-10-11 |
JP2021525783A (ja) | 2021-09-27 |
EP3805217A1 (fr) | 2021-04-14 |
EP3805217A4 (fr) | 2022-03-23 |
AU2019280356A1 (en) | 2021-01-14 |
KR20210018915A (ko) | 2021-02-18 |
AU2019280356B2 (en) | 2022-09-29 |
CN112204024B (zh) | 2024-03-29 |
WO2019233457A1 (fr) | 2019-12-12 |
CN112204024A (zh) | 2021-01-08 |
TW202016102A (zh) | 2020-05-01 |
CA3103055A1 (fr) | 2019-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL282487A (en) | TYK2 inhibitors and their use | |
ZA202002172B (en) | Pde9 inhibitor and use thereof | |
IL289612A (en) | hpk1 inhibitors and uses thereof | |
EP3572400C0 (fr) | Inhibiteur de l'ezh2 et son utilisation | |
IL283409A (en) | tyk2 inhibitors and uses thereof | |
IL282090A (en) | tyk2 inhibitors and uses thereof | |
IL276489A (en) | ATR inhibitor and its application | |
IL282350A (en) | Bernani-RGMC inhibitors and their use | |
PL3621694T3 (pl) | Inhibitory lrrc33 i ich zastosowanie | |
EP3336091A4 (fr) | Inhibiteur d'irak4 et son utilisation | |
IL279276A (en) | ERK inhibitor and use thereof | |
EP3336090A4 (fr) | Inhibiteur de l'irak4 et son utilisation | |
IL291217A (en) | usp30 inhibitors and their uses | |
IL284514A (en) | Halo-allylamine compounds and their use | |
PT3712147T (pt) | Inibidor de sglts e sua aplicação | |
ZA202102192B (en) | Fgfr4 inhibitor and use thereof | |
ZA201905934B (en) | Dual magl and faah inhibitors | |
IL292198A (en) | Tim-3 inhibitors and their uses | |
IL285595A (en) | Spt5 inhibitors and uses thereof | |
IL280644A (en) | Magnesium serine compound and its use | |
IL286485A (en) | pi4-kinase inhibitors and methods of using them | |
EP3744722A4 (fr) | INHIBITEUR DE ß-LACTAMASE ET SON UTILISATION | |
IL283106A (en) | erk inhibitors and their uses | |
EP3892619A4 (fr) | INHIBITEUR SÉLECTIF DE PI3Ko ET SON UTILISATION | |
GB201908884D0 (en) | Inhibitors and use |